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Abstract
Background: Occupational and environmental exposure to crystalline silica may lead to the development of
silicosis, which is characterized by inflammation and progressive fibrosis. A substantial number of patients
diagnosed with silicosis develop pulmonary hypertension. Pulmonary hypertension associated with silicosis and
with related restrictive lung diseases significantly reduces survival in affected subjects. An animal model of
silicosis has been described previously however, the magnitude of vascular remodeling and hemodynamic effects
of inhaled silica are largely unknown. Considering the importance of such information, this study investigated
whether mice exposed to silica develop pulmonary hypertension and vascular remodeling.
Methods: C57BL6 mice were intratracheally injected with either saline or crystalline silica at doses 0.2 g/kg, 0.3 g/kg
and 0.4 g/kg and then studied at day 28 post-exposure. Pulmonary hypertension was characterized by changes in right
ventricular systolic pressure and lung histopathology.
Results: Mice exposed to saline showed normal lung histology and hemodynamic parameters while mice exposed to
silica showed increased right ventricular systolic pressure and marked lung pathology characterized by a granulomatous
inflammatory reaction and increased collagen deposition. Silica-exposed mice also showed signs of vascular remodeling
with pulmonary artery muscularization, vascular occlusion, and medial thickening. The expression of pro-inflammatory
genes such as TNF-α and MCP-1 was significantly upregulated as well as the expression of the pro-remodeling genes
collagen type I, fibronectin and the metalloproteinases MMP-2 and TIMP-1. On the other hand, the expression of several
vasculature specific genes involved in the regulation of endothelial function was significantly attenuated.
Conclusions: We characterized a new animal model of pulmonary hypertension secondary to pulmonary fibrosis
induced by crystalline silica. Our data suggest that silica promotes the damage of the pulmonary vasculature through
mechanisms that might involve endothelial dysfunction, inflammation, and vascular remodeling.
Keywords: Silicosis, Pulmonary hypertension, Vascular remodeling, Animal model
Background
Exposure to silica may occur in a variety of working and
living environments since crystalline silica is one of the
most abundant minerals on earth. For example, occupa-
tional expose to silica occurs during mining, stone cutting,
tunneling and quarrying [1]. Environmental exposure to
silica may occur during sand storms, during inhalation of
very fine particles of windblown soil, and following
volcanic eruptions. Chronic inhalation of crystalline
silica promotes the development of several diseases
such as silicosis, chronic obstructive pulmonary diseases
(COPD), and lung cancer [2, 3]. Silicosis is a fibrotic
pneumoconiosis characterized by nonneoplastic granu-
lomatous and fibrotic changes in the lung. Silica-exposed
patients remain asymptomatic for decades when eventu-
ally diagnosed by the presence of fine nodular opacities in
the lung by chest X-ray or CT-scan [4]. Depending of dose
and time of exposure, silica may produce acute or various
forms of chronic silicosis [5].
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In general, two major stages can be defined during
silicosis progression. First, an inflammatory stage char-
acterized by the release of inflammatory mediators such
as IL-1β, IL-6, TNF-α that can continue to be released
into the second fibrotic stage. The second state is a fibrotic
stage characterized by excess deposition of extracellular
matrix proteins such as collagen and fibronectin [6, 7].
Although the exact mechanisms responsible for these
changes remain unclear, it is well established that
inhaled silica particles are engulfed by macrophages,
which leads to cell activation and death followed by
the release of intracellular silica that is then taken up
by other macrophages. This recurring cycle of cell
death and macrophage activation produces the influx
of inflammatory cells and the production of cytokines
and reactive oxygen and nitrogen species [8]. These in-
flammatory mediators are able to enter the pulmonary and
systemic circulations where they can produce vascular
injury. Moreover, ultra-fine silica particles may cross
the pulmonary epithelium into the vascular bed and
directly affect the integrity of the vascular endothelium
[9, 10]. Interestingly, cardiovascular diseases are among
the leading causes of death in patients with silicosis [11].
The recurring injury to the pulmonary vasculature
may lead to the development of pulmonary hypertension.
Pulmonary hypertension results from a proliferative
vasculopathy of the small pulmonary arteries and arterioles
of the lung best characterized by vasoconstriction, cellular
hyperplasia, fibrosis, and thrombosis. These constricted or
blocked arteries lead to increased pressure in the vessels
and in the right ventricle of the heart. If left untreated, the
right ventricular chamber hypertrophies leading to pre-
mature right heart failure. In the United States, about
200,000 hospitalizations occur annually due to pulmonary
hypertension as primary or secondary diagnosis. About
15,000 deaths per year are ascribed to pulmonary hyper-
tension, although this is likely a low estimate [12]. The
contribution of silicosis to these statistics is likely small,
but it has been shown that pulmonary hypertension in pa-
tients with silicosis is linked with poorer prognosis [13].
Similarly, COPD and diffuse parenchymal lung diseases,
including idiopathic lung fibrosis and sarcoidosis, are as-
sociated with a high incidence of pulmonary hypertension
[14, 15]. Patients with combined interstitial lung disease
and pulmonary hypertension have significantly lower sur-
vival rate and quality of life.
Because of its clinical relevance, elucidating the
mechanisms by which silicosis may lead to pulmonary
hypertension is considered important. Animal models
of silica exposure exist and, as observed in humans,
silica induces granulomatous changes in the lungs of
these animals, resulting from the loose aggregation of
activated foamy histiocytes and lymphocytes or well
organized nodular structures consisting of epitheloid
macrophages and multinucleated giant cells [16, 17].
However, there are currently no well-described in vivo
models of silica exposure that demonstrate increased
risk of pulmonary vascular remodeling and pulmonary
hypertension. The objective of this study was to determine
whether silica exposure leads to increased right ventricular
systolic pressure (RVSP) and vascular remodeling in pul-
monary arteries. We now provide evidence that RVSP and
vascular abnormalities are markedly increased in silica-
exposed mice compared to control mice.
Methods
Experimental animals and animal care
The research protocol was approved by the Institutional
Animal Care and Use Committee of the University of
Louisville, and the care and handling of the animals were
in accordance with National Institutes of Health guidelines.
C57BL6 mice were obtained from Jackson Laboratory (Bar
Harbor, ME).
Animal model
Adult male C57BL6 mice (10 weeks of age) were separated
into 5 experimental groups with 5 animals per group.
Animals were anesthetized and placed in the supine
position. Using sterile technique, the trachea was ex-
posed via midline neck incision followed by instillation
of silica or saline. Crystalline silica was sterilized at
200 °C for 2 h to inactivate endotoxin contamination.
Silica suspension in sterile 0.9% NaCl was prepared by
vigorous vortexing immediately prior to intratracheal
administration. Using a 27-gauge needle attached to a
microliter syringe, 0.2 g/kg, 0.3 g/kg and 0.4 g/kg of
crystalline silica suspension or the equivalent volume of
saline was instilled into the trachea. The fifth group of
mice was instilled with 3.5 U/kg of bleomycin (APP
Pharmaceuticals, Schaumburg, IL). The incision was
then closed using surgical clips, and animals were
allowed to recover. Twenty-eight days after intratracheal
instillation of silica, RSVP parameters were measured and
lung and heart tissues were harvested for morphological,
biochemical, and histochemical analyses. Bleomycin-
injected mice (3.5 U/kg) were used as positive control
and were analyzed 21 days later. Tissue was immediately
processed or quick-frozen in liquid nitrogen.
Reagents
Primers and probes for real-time PCR were obtained
from Integrated DNA and ThermoFisher Scientific. All
other chemicals and enzymes were from Sigma Chemical
Co. (St. Louis, MO), or Invitrogen (Carlsbad, CA).
Crystalline silica was a gift from US Silica (Min-U-Sil-5,
US Silica, Frederick, MD).
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Hemodynamic measurements
RVSP was determined with a 1 F pressure transducer
catheter (Millar Instruments) and LabChart 8 software
(AD Instruments). Briefly, the 1 F pressure transducer
was inserted through the right external jugular vein of
anesthetized mice (100 mg ketamine/5 mg xylazine/kg
of body weight, i.p.). Mice were placed on thermal plates
to keep body temperature constant at 37 °C. Then, a pres-
sure catheter was threaded into the right ventricle and
RVSP was recorded using PowerLab 4/35 (AD Instruments)
and analyzed using LabChart 8 software.
Lung and heart histology
Heart and lungs were flushed with PBS and inflated and
fixed with 10% formalin overnight, then embedded in
paraffin, sectioned at a thickness of 5 μm, and stained
with Mason’s trichrome to visualize lung morphology,
fibrosis and vascular remodeling. Images were captured
by a high-resolution digital camera connected to a light
microscope using 4× and 40× magnification lenses. The
evaluation and image analysis procedures were performed
using ImageJ software.
Immunohistochemical staining of mouse lungs for
smooth muscle, von Willebrand Factor (vWF), LY-6B and
CD107b
Longitudinal sections (5 μm) of left lung lobe were
hydrated and antigen retrieval was first performed by
incubating with 0.1% pronase for 5 min at 37 °C and
then heating the slides in 10 mM sodium citrate
(pH 6.0) plus 0.05% Tween 20 at 98 °C for 10 min.
Sections were stained with anti-smooth muscle actin-
alpha antibodies clone 1A4 (Sigma) at concentration
23 ng/μl, anti-vWF antibodies H-300 (Sigma), anti-LY-6B
and anti CD-107b antibodies (Bio-Rad) at concentration
10 ng/μl. After washing, the slides were incubated with
secondary antibodies labeled with either AlexaFluor 488
or AlexaFluor 594. To determine the specificity of
staining, lung sections were incubated with control,
non-immune IgG. Slides were analyzed with fluores-
cent microscopy. Images were processed using ImageJ
(National Institutes of Health, Bethesda, MA). Pulmonary
arteries were defined as vessels that accompanied airways
(veins are interlobular). To measure percent of area
stained with specific marker of neutrophils and macro-
phages we used ImageJ software. For silica and bleo-
mycin treated lung at least four different areas showing
pulmonary arteries and silicotic granulomas or fibrotic
lesions were selected. The stained areas were selected
by thresholding and then calculated using particles
analysis extension of ImageJ. The same parameters for
thresholding and for calculation of particles were ap-
plied to all images.
Right ventricular hypertrophy
After hemodynamic measurements, the hearts were re-
moved and right and left ventricles and septum were sepa-
rated. The ratio of the right ventricular weight to the sum
of left ventricular and septal weight (RV/[LV + S]) served as
a measure for right ventricular hypertrophy.
Granuloma area calculation
In sections stained with Mason’s trichrome, the total
area of lung section and granuloma area were determined
using ImageJ software. Three to four images of each lung
were taken at 40× magnification to cover entire lung lobe.
Granuloma area percentage was calculated by dividing
granuloma area by total lung area and multiplying by 100.
Pulmonary vessels morphometry
To assess muscularization of pulmonary vessels, all
blood vessels ranging from 10–100 μm in diameter were
counted in at least four fields at 40× magnification. The
counted vessels were categorized as fully muscularized
(95–100% of medial layer covered by anti-αSMA staining),
partially muscularized (1–95% of medial layer is covered
by anti-αSMA staining), or nonmuscularized vessels. The
percentage of pulmonary vessels in each category was
calculated by dividing the number of vessels in the
category by the total number of counted vessels in the
same field.
Morphometric analysis
The diameter and wall thickness of arteries were measured
using ImageJ software, after the number of pixels were cali-
brated according to the scale bars for each magnification.
The values of medial wall thickness were calculated as
outer diameter minus inner diameter divided by 2. At
least four vessels were counted for each mouse lung. The
analysis and measurement of α-SMA staining was evalu-
ated by an investigator blinded to treatment groups.
Quantitative RT-PCR
Total RNA was prepared from the superior lobe of right
lung using RNAqueous-Micro Kit (Applied Biosystems,
Foster City, CA). The synthesis of single stranded DNA
from RNA was performed using SuperScript First-Strand
Synthesis System for RT-PCR and random hexamers
(Invitrogen, Carlsbad, CA), according to the protocol
provided by manufacturer. To quantitate the abundance
of gene-specific mRNAs, quantitative PCR was undertaken
using the StepOnePlus Real-Time PCR Detection System
(Applied Biosystems) and an SYBR® Green Master Mix. The
PCR cycles were 95 °C for 3 min, then 40 cycles of 95 °C for
15 s, 60 °C for 1 min. The mouse fibronectin primers were
forward (5′- GAC TGT ACT TGT CTA GGC GAA G -3′)
and reverse (5′-GTT TCC TCG GTT GTC CTT CT-3′),
mouse PECAM-1 primers were forward (5′-AGA GAC
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GGT CTT GTC GCA GT-3′) and reverse (5′-TAC TGG
GCT TCG AGA GCATT-3′), mouse Endothelin 1 primers
were forward (5′- TCT GCA CTC CAT TCT CAG C-3′)
and reverse (5′- CGT GAT CTT CTC TCT GCT GTT
C-3′), mouse Platelet Factor 4 (PF4) primers were for-
ward (5′- ACC ATC TCC TCT GGG ATC CAT-3′)
and reverse (5′-CCA TTC TTC AGG GTG GCT ATG
AG-3′), mouse Nestin primers were forward (5′-GGA
AAG CCA AGA GAA GCC T-3′) and reverse (5′-CAC
CTC AAG ATG TCC CTT AGT C-3′). PCR assays
were run in triplicate, and gene expression was normal-
ized to β-Actin mRNA levels. Primers for β-Actin were
forward (5′- ACA GCT TCT TTG CAG CTC CT-3′)
and reverse (5′-CCA TCA CAC CCT GGT GCC TA-3′).
Analysis of Col1a1, Timp1, Ctgf, Tnf and Mmp2 were per-
formed using custom gene expression assays with FAM
labeled probe obtained from Applied Biosystems. The
mRNA levels for these genes were normalized for β-Actin
mRNA levels that were detected with custom gene expres-
sion assay with VIC labeled probe.
Data analysis
Values were expressed as means ± SEM. Comparisons
between multiple independent groups were made by
using One-way ANOVA followed by post hoc analysis
with the Holm-Sidak test. Data of two groups were com-
pared with unpaired t-test. A p-value of <0.05 indicated
statistically significant differences.
Results
Silica exposure causes weight loss
Instillation of increasing amounts of crystalline silica
into the trachea of animals led to the progressive loss of
body weight at day 2 and day 4 after the start of the
treatment (Fig. 1a). With a silica dose of 0.4 g/kg, mice
lost up to 16% of their body weight, but regained close
to the weight of the control group by day 14. This quick
recovery of body weight is in contrast with our observa-
tions after bleomycin treatment where weight loss was
more severe and maximum body weight loss was observed
around day 10 (data not shown). Bleomycin-treated mice
did not regain their body weight to the level of control
mice even at day 21. Similarly to the weight loss, survival
of mice after treatment was affected only in the bleomycin
group (2 mice out of total 5 mice died (40% mortality).
Silica-induced lung fibrosis
To confirm the effects of silica instillation on the patho-
genesis of lung inflammation and fibrosis, the lung tis-
sues of mice were observed using light microscopy to
monitor pathological changes. No obvious abnormalities
were evaluated in the lungs of mice that received saline
at days 28 (Fig. 1b, Left Image). Conversely, cellular nod-
ules, fibrotic bands, and marked collagen deposition
determined by trichrome staining were observed in the
silica-treated groups. Quantitative analysis of the area of
the fibrotic nodules indicated significant and dose-
dependent increase of lesion area in the lung of silica-
treated mice (Fig. 1c). These data correlated with loss of
body weight depicted in Fig. 1a.
Crystalline silica increases right ventricle (RV) systolic
pressure
To evaluate the dose-dependent effects of silica on right
ventricle systolic pressure (RVSP), mice were anesthe-
tized and RV systolic pressure was measured using
pressure catheter. Significant changes in RVSP were
observed in silica-treated mice (from 22.65 ± 1.01 mmHg in
control to 30.75 ± 1.28 mmHg; p < 0.05) in mice treated
with silica at dose 0.4 g/kg (see Fig. 2a). Treatment of mice
with bleomycin increased RVSP to 49.21 ± 8.276 mmHg
(Fig. 2b). However, no changes in RV hypertrophy mea-
sured as ratio of RV/(S + LV) were observed (Fig. 2c).
These data indicate that silica exposure induced pulmonary
hypertension, but the latter was either not severe enough to
cause RV hypertrophy or more time was required to
observe these effects.
Morphological changes in pulmonary arteries of silica-
treated mice
Next, we analyzed the effect of silica on pulmonary
vascular remodeling. Control mice showed normal pul-
monary artery structures (Fig. 3a-c). Mice exposed to
crystalline silica through intratracheal instillation developed
marked vascular remodeling. The most obvious vascular
abnormalities observed were detected near inflammatory
granules and fibrotic lesions. The representative images
presented in Fig. 3d-f indicated that pulmonary arteries
showed vascular wall thickening (see arrows). In addition,
vessels located in close proximity to inflammatory nodules
in some cases became completely surrounded by inflamma-
tory cells (Fig. 3g) and/or surrounded by collagen fibrils
(Fig. 3h). Intimal hypertrophy was observed in some pul-
monary vessels (Fig. 3i). These histological observations
indicate that pulmonary vascular walls undergo significant
remodeling in the lungs of silica-treated mice.
Induction of inflammatory and extracellular matrix genes
Quantitative real-time PCR was performed to measure
the levels of collagen type I (Col1a1), fibronectin (Fn1),
TIMP-1, MMP-2, CTGF and TNF-α mRNAs in the right
lung. The mRNA expression of collagen type I and fibro-
nectin was markedly elevated the lungs of animals exposed
to silica at a dose of 0.3 g/kg and 0.4 g/kg, indicating the
induction of pro-fibrotic genes in silica-treated lungs
(Fig. 4a-b). Even greater increases were detected for
mRNA levels of TIMP-1 (7 fold) and of MMP-2; (2.2
fold), over control mice (Fig. 4c-d). The expression of
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pro-inflammatory mediators TNF-α and MCP-1 was
also increased from 3- to 5-fold compared to control
mice (Fig. 4f and data not shown). Increases in the
mRNA expression of these genes were also detected in
the bleomycin model (Fig. 4g). On the other hand, no
induction of CTGF mRNA expression was observed in
silica-treated mice in contrast to bleomycin-treated
lungs (Fig. 4e and g). Interestingly, while expression of
Col1a1, Fn1, Timp1 and Mmp2 genes was induced to a
higher extent in bleomycin-treated lungs compared to
silica-treated lungs, the expression of the TNF-α gene
was unchanged in the bleomycin group (Fig. 4g). These
data indicate that silica induces significant changes in
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Fig. 1 Weight loss and silicotic nodules in mice treated with crystalline silica. C57BL6 male mice were intratracheally injected with different
amount of crystalline silica suspension. Mice were sacrificed 28 days later. a, Silica-induced body weight changes in mice were measured at 2, 4,
7, 14, 21 and 28 days following silica administration. Mice receiving higher doses of silica showed more weight loss. Results are expressed as the
mean of five mice +/− SD. b, Morphologic evidence of silica-induced lung injury. Representative images of lung from control and silica-treated
mice. Arrows indicate granulomatous lesions. c, Quantitative analysis of granulomatosis in lung of silica-treated mice. *p < 0.05 when compared
between treatments, One Way ANOVA with Holm-Sidak post test
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Fig. 2 Elevation of right ventricular systolic pressure in mice treated with silica. Mice treated with different concentration of silica for 28 days (a)
or bleomycin for 21 days (b) were analyzed for right ventricle systolic pressure (RVSP) using 1 F pressure-transducer catheter (Millar). c, Ratio of
right ventricle (RV) to left ventricle (LV) plus septum (S) was determined by dissecting RV from LV and S. The results are shown as mean ± SEM,












Fig. 3 Histological analysis of vascular abnormalities in lung from silica-treated mice. Mouse lung were stained with Mason’s trichrome and
imaged using 400× magnification. Panel a-c: representative images of pulmonary arteries from control mice. Panel d-i: images of pulmonary
arteries with different vascular abnormalities. Vascular wall thickening (d-f); inflammatory cells and collagen deposition around pulmonary arteries
(g-h); endothelial proliferation (i)







Fig. 4 (See legend on next page.)
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in the mouse lung, but there are some differences when
compared to the bleomycin model.
Silica promotes pathological signs of pulmonary vascular
remodeling and medial thickening
In order to identify vascular abnormalities in silica-
treated mice, lung sections were stained with antibodies
specific for α-smooth muscle actin (for smooth muscle
cells) and von Willebrand Factor (for endothelial cells).
While the vasculature from control mice showed normal
pulmonary artery architecture (Fig. 5a images a-c), vascu-
lar remodeling was apparent in the lungs of mice exposed
to crystalline silica (Fig. 5a images d-i). Interestingly, a
complex stalk-like lesion was detected within a blood ves-
sel lumen (Fig. 5a image h). It was formed just distal to a
dichotomous branching point. The body of the lesion ap-
peared to be a disorganized hyperchromatic accumulation
of cells that were covered by von Willebrand factor–posi-
tive endothelial cells. The stalk-like structure appeared to
arise from the arterial wall and extend downstream into
the lumen of the vessel (Fig. 5a image f). Moreover, quan-
titative analysis of medial wall thickness indicated signifi-
cant increase in thickness of smooth muscle layer from
4.85 ± 0.42 μm in control lung to 9.14 ± 0.93 μm (p < 0.05)
in silica treated lung and to 10.21 ± 1.04 μm (p < 0.05) in
bleomycin treated lung (Fig. 5b).
Muscularization of pulmonary arteries in response to
silica
Treatment of mice with both silica and bleomycin resulted
in a decrease in the number of non-muscularized pulmon-
ary vessels (Fig. 6a). These changes were associated with
significant increases in partially muscularized and fully
muscularized vessels. Treatment with 0.4 g/kg silica in-
creased the percent of partially muscularized vessels from
26.85 ± 2.03 to 33.51 ± 1.92 (p < 0.05). At the same time,
the percentage of fully muscularized vessels increased
from 13.63 ± 1.18 in control mice to 17.67 ± 1.69 (not sig-
nificant) in silica-treated mice and to 22.30 ± 2.36 (p <
0.05) in bleomycin treated mice (Fig. 6c). Thus, our data
indicate that crystalline silica and bleomycin produced
comparable changes in pulmonary vessel muscularization.
Modulation of vascular-specific gene expression in silica-
treated mice
Exposure of murine lung to crystalline silica for 4 weeks
attenuated the expression of several endothelium- or
smooth muscle-specific genes (Fig. 7). Expression of the
endothelium-specific gene CD31 was downregulated both
in silica- and bleomycin-treated mice (Fig. 7a). A similar
pattern of attenuated expression was observed for
platelet factor 4 (Fig. 7b). On the other hand, expres-
sion of endothelin 1 remained only slightly attenuated
without reaching statistically significant levels in both
treatment groups (Fig. 7d), while expression of nestin
was attenuated only in silica-treated mice (Fig. 7c).
These data indicate that crystalline silica attenuated the
expression of genes involved in regulation of cardiopul-
monary homeostasis quite similar to bleomycin.
Increased influx of inflammatory cells into lung of mice
treated with silica
Mice treated with silica at concentration of 0.4 g/kg
showed significantly higher number of inflammatory
cells stained with antibodies specific for LY-6B and
CD107b in the lung (Fig. 8). Neutrophils and macro-
phages were observed mostly in the areas of granuloma
location. They were also deposited around vessels adja-
cent to the lesions (Fig. 8a, images b and e). Surprisingly,
we did no observed significant increase in activated per-
ipheral neutrophils in the lung exposed to bleomycin for
21 day (Fig. 8a, image c). In contrast, the number of cells
stained with macrophage specific antigen CD107b was
increased in bleomycin treated group (Fig. 8a, image e).
Quantitative analysis indicates that the CD107b stained
area increased from 2.11 ± 0.28% in control lung to
41.31 ± 5.38% (p < 0.05) in silica treated lung and to
17.01 ± 3.23% (p < 0.05) in bleomycin treated lung
(Fig. 8b). Similarly, the area stained with the neutrophil
specific marker LY-6B was increased from 1.06 ± 0.17%
in control lung to 6.06 ± 1.46% (p < 0.05) in silica-treated
lung, while no significant changes were observed in
bleomycin-treated lungs (Fig. 8b). These data indicate
that crystalline silica produced robust inflammatory
response that persists even 28 days following initial
administration. Attenuated inflammatory staining in
bleomycin treated lungs indicated that lung tissues
most likely undergo fibrotic remodeling with subsided
inflammatory phase.
Discussion
Despite efforts to prevent occupational exposure to crystal-
line silica dust, silicosis continues to occur in many devel-
oping nations in Asia and South America, and still remains
(See figure on previous page.)
Fig. 4 Silica exposure increases pro-fibrotic gene expression. Analysis of gene expression in the lung of silica treated mice (panels a-f). Whole lung
mRNA levels for collagen type I, alpha 1 (Col1a1), fibronectin 1 (Fn1), tissue inhibitor of metalloproteinases 1 (Timp1), matrix metalloproteinase 2
(Mmp-2), connective tissue growth factor (Ctgf) and tumor necrosis factor alpha (TNF-α) were determined using real-time PCR and normalized to
beta-acting expression (β-Actin). g, Changes in gene expression in the lung of bleomycin treated mice at 21 days. The results are shown as mean ± SEM,
*p< 0.05 when compared to control lung, One Way ANOVA with Holm-Sidak post test
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a significant hazard in advanced countries of North
America and Europe [18]. Although this disease can be
prevented by introducing safer working conditions,
equally important is the development of early diagnostic
tools and safe and effective therapies for those diagnosed
with this devastating disease. Animal models remain an
important tool in studying the genesis and the progression
pulmonary vascular diseases associated with chronic lung
disorders. However, despite strong epidemiologic links
between exposure to silica and development of pulmonary
hypertension in humans [19], there have been no mouse
models described to our knowledge that confirm this
association and can be used to elucidate the underlying
mechanism(s) responsible. Several previous studies ana-
lyzed the effects of asbestos on pulmonary hemodynamic
and vascular abnormalities in guinea pigs and rats [20, 21].
The current work suggests that 4 weeks of exposure to
crystalline silica is associated with increases in RVSP,
vascular remodeling and dysregulation of genes involved
in maintenance of vascular homeostasis.
To compare the effects of silica with other injurious
agents, we used mice exposed to bleomycin as a model
of severe pulmonary hypertension secondary to lung
chronic diseases. While many similarities were observed
between the two models, we identified several distinctive
features that were only seen in silica-exposed mouse
lungs. First, the increase in RVSP observed in the silica
model was markedly less profound compared to bleo-
mycin model. This difference can be attributed to dosing












Fig. 5 Abnormal endothelial and smooth muscle remodeling in the pulmonary vasculature of silica-treated mice. a, Lung sections (5 μm thick)
were stained with antibodies specific for endothelium-specific von Willebrand Factor vWF (red) and α-smooth muscle actin (green). Nuclei were
stained using DAPI (blue). Images were taken using 40× objective. Panel a-c: representative images of pulmonary arteries from control mice. Panel
d-i: images of pulmonary arteries with different vascular abnormalities: increased accumulation of inflammatory cells around vessel (e), intimal
obliteration and/or luminal occlusion by vWF-positive cells (f and h), neointimal proliferation (g and i). Bar = 100 μm. b, Quantitative analysis of
medial wall thickness in pulmonary arteries. *p < 0.05 when compared to control lung, One Way ANOVA with Holm-Sidak post test
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its effects on the pulmonary vasculature and hemodynamic
is not well understood. It is possible that silica-particles
trapped within the lung parenchyma are quickly sur-
rounded by aggregates of thrombocytes and mono-
nuclear leukocytes, raising the likelihood that regional
vasoconstriction triggered in response to focally released
thromboxane or serotonin could substantially amplify the
overall increase in pulmonary vascular resistance [22, 23].
On the other hand, it is possible that reduced cardiac out-
put can significantly obscure pulmonary vascular resistance.
Unfortunately, we do not have adequate state-of-the-art
equipment to test these possibilities. During the last decade,
the proinflammatory cytokines TNF-α and IL-1β have
emerged as biomarkers and mediators of oxidative stress
and endothelial dysfunction in several cardiovascular
diseases [24]. In the present study, we observed that
pulmonary arteries from silica-exposed animals showed
enhanced TNF-α gene expression despite there being
no changes in IL1-β (data not shown). In addition, in-








































































Fig. 6 Muscularization of pulmonary arteries in silica- and bleomycin-treated mice. Lung sections were stained with vWF (red) and alpha-smooth
muscle actin (green) specific antibodies. Nuclei were stained using DAPI (blue). Representative images of non-muscularized (a), partially muscularized
(b) and fully-muscularized (c) arteries showed on left side. Quantitative analysis of pulmonary arteries remodeling presented on right side. Significant
increase in partially-muscularized and fully muscularized arteries was detected in silica (0.4 g/kg) and bleomycin-treated lungs
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recruitment of more inflammatory cells such as neutrophils
and macrophages to the site of injury in silica-treated lungs.
Our data indicate that elevated TNF-α gene expression
correlates with infiltration of macrophages and neutrophils
into silica-induced fibrotic lesions. On the other hand,
levels of TNF-α and number of neutrophils did not increase
significantly in bleomycin-induced fibrotic lesions. Thus,
inhaled silica particles could directly induce endothelial
dysfunction by stimulating TNF-α expression and/or by
increasing inflammatory cell recruitment in response to
elevated secretion of pro-inflammatory cytokines.
We also observed increased expression of MMP-2 and
TIMP-1 in lung tissue of silica-exposed mice. MMPs are
involved in remodeling of the alveolar architecture near
granulomatous lesions but, at the same time, can influ-
ence the composition and remodeling of vascular wall.
In response to angiogenic stimulus, endothelial-derived
MMPs mediate proteolytic degradation of endothelial
cell-cell interactions, which promotes a proliferative and
migratory phenotype in endothelial cells [25]. In addition,
increased MMP-2 and TIMP-1 expression were identi-
fied in pulmonary artery smooth muscle cells isolated
from idiopathic PAH patients [26]. Importantly, in-
creased gelatinolytic activity was mainly observed in
the medial layer, and correlated with increased MMP-2
expression in the pulmonary arteries of monocrotaline-
treated animals [27]. This gelatinolytic activity can be
attributed to MMP-2 since expression of MMP-9 gene
in the pulmonary hypertension model was not observed.
The correlation between MMP-2 expression and progres-
sion of pulmonary hypertension in the described animal
model indicated important roles of this proteinase in
different vascular remodeling processes that involves
smooth muscle cell proliferation, migration and intimal
thickening. The other source of increased MMP-2 and
TIMP-1 mRNA levels might be adventitial fibroblasts.
Progressing granulomatosis can promote hypoxemia in
the lung tissues of silica-treated mice. It has been
shown that hypoxia significantly increased MMP-2,





Fig. 7 Expression of vascular-specific genes. Analysis of gene expression in the lung of silica- and bleomycin-treated mice (panels a-d). Expression
of genes was analyzed 28 days following silica instillation and 21 days following bleomycin instillation. Whole lung mRNA levels for PECAM-1
(CD31), platelet factor 4 (PF4), nestin and endothelin 1 were determined using real-time PCR and normalized to beta-acting expression (β-Actin).
The results are shown as mean ± SEM, *p < 0.05 when compared to control lung, One Way ANOVA with Holm-Sidak post test
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expression in adventitial fibroblasts and promoted neo-
intimal hyperplasia [28].
The increase of collagen type I (Col1a1) mRNA levels
coinciding with muscularization and thickening of pul-
monary vascular wall indicates collagen accumulation
in the vasculature. The phenotype switch of pulmonary
smooth muscle cell to hypertrophic cells can be regu-
lated by changes in homeostasis of extracellular matrix
components like vascular collagen, elastin and fibronec-
tin. Increased expression and deposition of collagen are
known to be important determinants of medial thickening
during the progression of PAH [29]. Collagen accumulation
increases pulmonary arterial stiffening, which translates
into pulmonary hypertension progression and eventually,
RV dysfunction [30].
We observed significant downregulation in expression
of endothelium specific genes such as Pecam 1, also known
as CD31, platelet factor 4 (PF4), and nestin. Pecam-1 is
expressed on the cell surface of endothelial cells as well as
hematopoietic and immune cells including platelets,
neutrophils and monocytes. TNF-α and IFN-gamma can re-
duce the expression of Pecam-1 and transmigration of
leukocyte in endothelial cells [31]. Mice deficient in Pecam-1






























































Fig. 8 Influx of inflammatory cells in the lung of mice treated with silica and bleomycin. a, Lung sections (5 μm thick) were stained with
antibodies specific for neutrophil-specific marker LY-6B (red), macrophage-specific marker CD107b (red) and α-smooth muscle actin (green). Nuclei
were stained using DAPI (blue). Images were taken using 20× objective. Representative images of mouse lung from control (images a and d),
0.4 g/kg silica treated (images b and e) or bleomycin treated (images c and f) mice. Increased accumulation of inflammatory cells around vessel
(images b and e) found in silica treated lungs. Bar = 200 μm. b, Quantitative analysis of area stained with corresponding specific antibodies. *p < 0.05
when compared to control lung, One Way ANOVA with Holm-Sidak post test
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demonstrate enhanced aggregation and formation of larger
thrombi in vitro under physiologic flow conditions [32, 33].
Nestin downregulation in vascular smooth muscle cells
represented an early event in vascular disease in experi-
mental type I diabetes [34]. On the other hand, vascular
cells expressing nestin were implicated in the develop-
ment of pulmonary hypertension [35]. Platelet factor 4
(PF4) expression was downregulated in human lung tissue
derived from patients diagnosed with pulmonary hyper-
tension secondary to pulmonary fibrosis, but up-regulated
in PAH patients [36]. A major physiological role of PF4 is
to neutralize heparin-like molecules on the endothelial
surface of blood vessels, thereby promoting coagulation
and inhibiting angiogenesis. One physiological role of PF4
in endothelial cells is to inhibit endothelial cell growth
through multiple signaling mechanisms [37]. Thus, down-
regulation of PF4 gene expression in our silica-induced
model of pulmonary hypertension might promote angio-
genesis and vascular remodeling in affected lungs.
Conclusions
We demonstrated that exposure of mice to a single
intratracheal instillation of crystalline silica causes pul-
monary vascular remodeling and pulmonary hyperten-
sion in mice, although these changes were less severe
than those observed in bleomycin-treated mice. To our
knowledge, this is the first study to establish that silica
exposure causes vascular abnormalities and mild elevated
RVSP in mice. Additionally, we observed significant
changes in the expression of genes responsible for inflam-
matory and fibrotic responses in pulmonary cells as well
as genes involved in regulation of vascular function.
Together, these observations begin to unveil a mechan-
istic link between silicosis and pulmonary hypertension.
Furthermore, they suggest that the silica-induced mur-
ine model of pulmonary hypertension could become a
valuable tool to explore the pathogenesis of this disease
in humans.
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